Oncotarget

Research Papers:

Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells

Stephen L. Hayward, Christina L. Wilson and Srivatsan Kidambi _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:34158-34171. https://doi.org/10.18632/oncotarget.8926

Metrics: HTML 1684 views  |   ?  


Abstract

Stephen L. Hayward1, Christina L. Wilson1, Srivatsan Kidambi1,2,3,4,5

1Department of Chemical and Biomolecular Engineering, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA

2Nebraska Center for Materials and Nanoscience, Lincoln, University of Nebraska-Lincoln, Lincoln, NE, 68588, USA

3Nebraska Center for the Prevention of Obesity Diseases, University of Nebraska-Lincoln, NE, Lincoln, 68583, USA

4Mary and Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, Omaha, NE, 68198, USA

5Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha NE, 68198, USA

Correspondence to:

Srivatsan Kidambi, email: skidambi2@unl.edu

Keywords: glioblastoma, nanomedicine, CD44 targeting, lipid nanoparticles, hyaluronic acid

Received: January 18, 2016     Accepted: March 04, 2016     Published: April 22, 2016

ABSTRACT

Glioblastoma Multiforme (GBM) is a highly prevalent and deadly brain malignancy characterized by poor prognosis and restricted disease management potential. Despite the success of nanocarrier systems to improve drug/gene therapy for cancer, active targeting specificity remains a major hurdle for GBM. Additionally, since the brain is a multi-cell type organ, there is a critical need to develop an approach to distinguish between GBM cells and healthy brain cells for safe and successful treatment. In this report, we have incorporated hyaluronic acid (HA) as an active targeting ligand for GBM. To do so, we employed HA conjugated liposomes (HALNPs) to study the uptake pathway in key cells in the brain including primary astrocytes, microglia, and human GBM cells. We observed that the HALNPs specifically target GBM cells over other brain cells due to higher expression of CD44 in tumor cells. Furthermore, CD44 driven HALNP uptake into GBM cells resulted in lysosomal evasion and increased efficacy of Doxorubicin, a model anti-neoplastic agent, while the astrocytes and microglia cells exhibited extensive HALNP-lysosome co-localization and decreased antineoplastic potency. In summary, novel CD44 targeted lipid based nanocarriers appear to be proficient in mediating site-specific delivery of drugs via CD44 receptors in GBM cells, with an improved therapeutic margin and safety.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8926